Literature DB >> 23496210

Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.

D M Larsen1, S L Haberichter, J C Gill, A D Shapiro, V H Flood.   

Abstract

Type 2M von Willebrand disease (VWD) includes qualitative defects in von Willebrand factor (VWF) function, with normal multimer distribution but a defect in VWF activity with respect to platelet or collagen binding. We characterized novel VWF gene mutations found in type 2M VWD subjects enrolled in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Subjects were enrolled based on a pre-existing diagnosis of type 2M VWD. Testing included full-length gene sequencing, VWF antigen (VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo), VWF collagen binding and multimer distribution. Recombinant VWF variants were synthesized using site-directed mutagenesis and expressed in HEK293T cells. Platelet binding was measured by flow cytometry with fixed platelets and ELISA with recombinant glycoprotein Ibα (GPIbα). Four novel VWF A1 domain mutations were found in individuals with type 2M VWD: S1358N, S1387I, S1394F and Q1402P. All subjects had a history of bleeding, VWF:RCo < 40 IU dL(-1) , VWF:RCo/VWF:Ag ratios <0.6 and normal multimer distribution. No defect in expression, secretion, or multimerization was found for any of the mutations. All showed decreased binding to intact platelets, and decreased or absent binding to a mutant GPIbα construct with spontaneous VWF binding. 1387I had decreased binding to all collagen types tested. 1402P had reduced binding exclusively to type VI collagen. Type 2M VWD is a heterogeneous category comprised of both collagen- and platelet-binding defects. Understanding the precise defect for each mutation may ultimately lead to better diagnosis and treatment.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23496210      PMCID: PMC3688679          DOI: 10.1111/hae.12117

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  25 in total

1.  Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease.

Authors:  V H Flood; J C Gill; P A Christopherson; J S Wren; K D Friedman; S L Haberichter; R G Hoffmann; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

Review 2.  Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease.

Authors:  D Meyer; E Fressinaud; C Gaucher; J M Lavergne; L Hilbert; A S Ribba; S Jorieux; C Mazurier
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

3.  Identification of a new type 2M von Willebrand disease mutation also at position 1324 of von Willebrand factor.

Authors:  L Hilbert; E Fressinaud; A S Ribba; D Meyer; C Mazurier
Journal:  Thromb Haemost       Date:  2002-04       Impact factor: 5.249

4.  von Willebrand factor binds to native collagen VI primarily via its A1 domain.

Authors:  M F Hoylaerts; H Yamamoto; K Nuyts; I Vreys; H Deckmyn; J Vermylen
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

5.  Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen.

Authors:  A S Ribba; I Loisel; J M Lavergne; I Juhan-Vague; B Obert; G Cherel; D Meyer; J P Girma
Journal:  Thromb Haemost       Date:  2001-09       Impact factor: 5.249

6.  Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets.

Authors:  D J Mancuso; P A Kroner; P A Christopherson; E A Vokac; J C Gill; R R Montgomery
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

7.  Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.

Authors:  Augusto B Federici; Claudine Mazurier; Erik Berntorp; Christine A Lee; Inge Scharrer; Jenny Goudemand; Stephan Lethagen; Ioana Nitu; Gerard Ludwig; Lysiane Hilbert; Pier M Mannucci
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

8.  von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib.

Authors:  Y Fujimura; K Titani; L Z Holland; S R Russell; J R Roberts; J H Elder; Z M Ruggeri; T S Zimmerman
Journal:  J Biol Chem       Date:  1986-01-05       Impact factor: 5.157

9.  Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III.

Authors:  F I Pareti; K Niiya; J M McPherson; Z M Ruggeri
Journal:  J Biol Chem       Date:  1987-10-05       Impact factor: 5.157

10.  A monomeric von Willebrand factor fragment, Leu-504--Lys-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX [corrected].

Authors:  H R Gralnick; S Williams; L McKeown; W Kramer; H Krutzsch; M Gorecki; A Pinet; L I Garfinkel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

View more
  9 in total

1.  Crucial role for the VWF A1 domain in binding to type IV collagen.

Authors:  Veronica H Flood; Abraham C Schlauderaff; Sandra L Haberichter; Tricia L Slobodianuk; Paula M Jacobi; Daniel B Bellissimo; Pamela A Christopherson; Kenneth D Friedman; Joan Cox Gill; Raymond G Hoffmann; Robert R Montgomery
Journal:  Blood       Date:  2015-02-06       Impact factor: 22.113

2.  Variable bleeding phenotype in an Amish pedigree with von Willebrand disease.

Authors:  Sweta Gupta; Meadow Heiman; Natalie Duncan; Jesse Hinckley; Jorge Di Paola; Amy D Shapiro
Journal:  Am J Hematol       Date:  2016-08-22       Impact factor: 10.047

Review 3.  Perils, problems, and progress in laboratory diagnosis of von Willebrand disease.

Authors:  Veronica H Flood
Journal:  Semin Thromb Hemost       Date:  2013-12-12       Impact factor: 4.180

Review 4.  von Willebrand factor, Jedi knight of the bloodstream.

Authors:  Timothy A Springer
Journal:  Blood       Date:  2014-06-13       Impact factor: 22.113

5.  Clinical and laboratory phenotype variability in type 2M von Willebrand disease.

Authors:  A L Doruelo; S L Haberichter; P A Christopherson; L N Boggio; S Gupta; S R Lentz; A D Shapiro; R R Montgomery; V H Flood
Journal:  J Thromb Haemost       Date:  2017-06-23       Impact factor: 5.824

Review 6.  What have we learned from large population studies of von Willebrand disease?

Authors:  Robert R Montgomery; Veronica H Flood
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

7.  Improving diagnosis of von Willebrand disease: Reference ranges for von Willebrand factor multimer distribution.

Authors:  Inge Vangenechten; Alain Gadisseur
Journal:  Res Pract Thromb Haemost       Date:  2020-07-16

8.  On the versatility of von Willebrand factor.

Authors:  Antoine Rauch; Nikolett Wohner; Olivier D Christophe; Cécile V Denis; Sophie Susen; Peter J Lenting
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-07-10       Impact factor: 2.576

9.  Combined effects of two mutations in von Willebrand disease 2M phenotype.

Authors:  Adriana I Woods; Juvenal Paiva; Ana C Kempfer; Debora M Primrose; Alicia N Blanco; Analía Sanchez-Luceros; María A Lazzari
Journal:  Res Pract Thromb Haemost       Date:  2017-12-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.